Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report)'s stock price was down 3.8% during mid-day trading on Wednesday . The stock traded as low as $1.99 and last traded at $2.00. Approximately 4,923,423 shares traded hands during mid-day trading, an increase of 7% from the average daily volume of 4,588,243 shares. The stock had previously closed at $2.08.
Analyst Upgrades and Downgrades
Several research firms have weighed in on VOR. Wall Street Zen lowered Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. Zacks Research raised Vor Biopharma to a "strong sell" rating in a report on Tuesday, August 12th. Finally, HC Wainwright raised Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy".
Check Out Our Latest Stock Analysis on VOR
Vor Biopharma Stock Performance
The firm has a market cap of $258.43 million, a P/E ratio of -0.15 and a beta of 2.05. The firm has a fifty day simple moving average of $2.10.
Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($2.18) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($1.61).
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
See Also
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
